Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099268 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 747
- Enrollment target
NCT00099268 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 747 participants.
The verdict
NCT00099268, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 747 participants
- Enrollment target
Study Summary
The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disease.
Interventions
- DRUG Carbidopa/levodopa/entacapone
- DRUG Immediate release carbidopa/levodopa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 747 participants |
| Start Date | 2004-09 |
| Est. Completion | 2008-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00099268
The ClinicalTrials.gov registry entry for NCT00099268 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 747 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Carbidopa/levodopa/entacapone is the first listed.
NCT00099268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00099268 about?
NCT00099268 is a clinical study titled "Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy". The CELC200A2401 study has been designed in order to evaluate the hypothesis that administering the combination carbidopa/levodopa/entacapone at the time that levodopa therapy is initiated results in a decrease in the risk of the development of motor complications for patients with Parkinson's disea...
What is the current status of trial NCT00099268?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 747 participants. The study started on 2004-09. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00099268?
The interventions under investigation include: Carbidopa/levodopa/entacapone (DRUG), Immediate release carbidopa/levodopa (DRUG).
Who is sponsoring clinical trial NCT00099268?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.